The high effectiveness of IL-17 and IL-23 blocking agents in diverse psoriasis populations can be attributed to their highly specific and finely tuned modulation of intricate inflammatory cascades implicated in the pathophysiology of the condition. The gene discussed is IL17A; the disease is psoriasis.